Prof. dr Lazar Popović  radi na Institutu za onkologiju Vojvodine, predavač je na Katedri za onkologiju Medicinskog fakulteta u Novom Sadu i član Stručnog veća Ženskog centra Milica

Usavršavao se u inostranstvu na prestižnim univerzitetima i klinikama sa čuvenim svetskim stručnjacima.

Prof. dr Lazar Popović je objavio brojne stručne radove u istaknutim međunarodnim i domaćim časopisima.

Održao je velik broj predavanja i edukacija na domaćim i međunarodnim seminarima.

Aktivno se bavi lečenjem karcinoma dojke, uroloških maligniteta (karcinom prostate, mokraćne bešike, testisa, bubrega)

i hematološkim malignitetima (Hodgkinov, non-Hodgkinov limfom, multipli mijelom, hronična limfocitna leukemija).

Prof. dr Lazar Popović je zaposlen na Klinici za internu onkologiju na Institutu za onkologiju Vojvodine od 2005. godine.

Završio je specijalizaciju iz intene medicine 2011. godine, a potom i subspecijalizaciju iz onkologije 2015. godine.

Prof. dr Lazar Popović doktorsku disertaciju iz oblasti non-Hodgkinovog limdoma odbranio je 2014. godine.

Od 2006. godine je zaposlen na katedri za onkologiju Medicinskog fakulteta u Novom Sadu, do 2014. godine kao asistent, a 2014. godine izabran je za docenta.

Znanje je usavršavao u inostranstvu:

2008. godine na Klinici Tenon, univerziteta Pierre i Maria Curie u Parizu, Francuska kod Prof. dr Jean Pierre Lotz i Prof. dr Joseph Gligorov.

Nakon toga 2016. godine kao stipendista ESMO (Evropskog udruženja medikalne onkologije) je boravio na

Oncology Institute Souther Switzreland u Bellinzoni, Švajcarska zajedno sa Prof. dr Franco Cavali, Prof. dr Michele Ghielmini,dr Emanuele Zucca i dr Olivia Pagani.

Autor je i koautor u tri međunarodne monografije i preko 60 radova u istaknutim međunarodnim i domaćim časopisima.

Održao je velik broj predavanja i edukacija na domaćim i međunarodnim seminarima.

Osim lečenja karcinoma dojke Doc. dr Lazar Popović se aktivno bavi lečenjem uroloških maligniteta (

karcinom prostate, mokraćne bešike, testisa, bubrega) i hematološkim malignitetima (Hodgkinov, non-Hodgkinov limfom, multipli mijelom, hronična limfocitna leukemija).

Oženjen je i otac dvoje dece.

EDUCATION:

1994-1998 Gymnasium “Jovan Jovanović Zmaj”, in Novi Sad, science and mathematics,

1998-2004 Medicical faculty, in Novi Sad, Medicine doctor average 9,39/10.

2008-2011 Specialisation: Internal medicine2013-2015 Subspecialisation: Oncology

2014 PhD“Significance of molecular markers expression in prognosis of diffuse large B-celllymphoma treated with immunochemotherapy

WORKING EXPIRIENCE:

2004-2005 One year intership: Clinic for nephrology and clinical immunology, Clinical Centreof Vojvodina.

2005-2011 Medical doctor: Clinic for medical oncology, Oncology Institute of Vojvodina

2011-2015 Medical doctor, Internal medicine consultant: Clinic for medical oncology,Oncology Institute of Vojvodina

2015- Medical doctor, Internal medicine consultant, oncology subspecialist: Clinic formedical oncology, Oncology Institute of Vojvodina

2006-2014 Teaching assistent: Department of oncology, Medical faculty, Univeristy of Novi Sad

2014- Assistant Professor: Department of oncology, Medical faculty, Univeristy of Novi Sad

EDUCATION and EXPIRIENCE

2008 Professional education: Tenon Hospital, Paris, Medical Oncology and stem celltransplantation unit (Prof Lotz/ Prof Gligorov)

2016 ESMO Clinical Unit Visit Fellowship Grant: Oncology Institute Southern Switzerland,Lymphoma Unit, Breast Cancer Unit,

Phase 1 Trials Unit (Prof Cavalli/Prof Ghielmini/DrZucca/Dr Pagani/Dr Stathis)

2006 Course “Apheresis on Cobe spectra”

2007 GCP course certificate

2012 GCP recerification Quintiles2008 EBMT-Lymphoma working party training course

2009 EBMT-Infectious diseases working party training course

2011 EBMT-Medical statistics course

2012 Top 10 Teaching assistantsat Medical Faculty of Novi Sad-Award of Students

MEMBERSHIPS:

BUON (Balkans Union of Oncology) member

ESMO (European Society for Medical Oncology) member

ESMO YO-National RepresentativeSLG (Serbian Lymphoma Study Group) member

SLD (Serbian Medical Society) member

​AROME JUNIOR executive board member-research co-ordinator

AJOC (AROME Junior Oncologist Committee)-hematological malignancies co-coordinator

AROME (Association of Radiotherapy and Oncology in the Mediterranean Area) nationalboard member

NOVI SAD ONCOLOGY CONGRESS 2009., 2010. and 2012. Head of Congress Secretariat

NOVI SAD ONCOLOGY CONGRESS 2014., 2015. Organizing committee member

ARCHIVE OF ONCOLOGY journal editor 2013-2015ARCHIVE OF ONCOLOGY journal Editor-in-Chief 2015-ONCOLOGY

INSTITUE OF VOJVODINA DRG IMPLEMENTATION TEAM 2013-2015

ONCOLOGY INSTITUTE OF VOJVODINA ACREDITATON TEAM (Medical oncologydept and Information technologies teams) 2014-2015

PROJECTS

“Maintaining Quality of Oncology Service in Autonomous Province of Vojvodina”-Educational Project, Minsitry of Health, Autonomous Province of Vojvodina 2015-2016

CLINICAL TRIALS:

PRINCIPLE INVESTIGATOR:

PHASE III:

The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin andGemcitabine/Carboplatin

Alone in Participants With Untreated Locally Advanced or Metastatic UrothelialCarcinoma

Who Are Ineligible for Cisplatin-based Therapy (Imvigor130)

PHASE I:

TO-TAS-102-107 A Phase 1, Open-Label, Study to Evaluate the Safety, Tolerabillity, andPharmacokinetics of

TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of RenalImpairment

PHASE III:

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy,

Safety, and Immunogeneicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in

Patients with Low Tumor Burden Follicular Lymphoma

PHASE III:

A Phase III, Open-Label, Multicenter, Randomized Study To Investigate TheEfficacy And Safety Of MPDL3280A (Anti−PD-L1 Antibody, Atezolizumab)

Compared WithChemotherapy In Patients With Locally Advanced Or Metastatic Urothelial Bladder Cancer AfterFailure With Platinum-Containing Chemotherapy

PHASE III:

A phase 3, multicenter, randomized, double-blind, active control study to evaluatethe safety and efficacy of IV pro-netupitant/palonosetron (260 mg/0.25 mg)

combination for theprevention of chemotherapy-induced nausea and vomiting in repeated chemotherapy cycles inpatients receiving highly emetogenic chemotherapy

PHASE IV:

DIREGL07274-Metastatic Castrate Resistant Prostate Cancer-Serbian

NTERESTS and KNOWLEDGE:

Breast cancer

Urological cancers

Lymphoma/CLL

Multiple myeloma

Biomarkers and signaling pathways in cancer

Target therapy

Autologous stem cell transplantation

Supportive care in cancer

Pharmacoeconomy and management

Clnical trials